|
23 Companies |
|
30 Products |
|
30 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
425 News |
|
| «123456789» |
- | Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: PATENT PLUS: Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters. (clinicaltrials.gov) - May 20, 2013
P2, N=18, Completed, Sponsor: Bayer
Active, not recruiting --> Completed
- ||| Trial completion: REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management (clinicaltrials.gov) - May 15, 2013
P=N/A, N=3515, Completed, Sponsor: Actelion
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial initiation date, Combination therapy: FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - May 5, 2013
P3, N=354, Completed, Sponsor: United Therapeutics
Active, not recruiting --> Completed Initiation date: May 2006 --> Oct 2006
- | Opsumit (macitentan) / Nippon Shinyaku, J&J
New P3 trial: SYMPHONYext: Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument (clinicaltrials.gov) - May 2, 2013
P3, N=4, Completed, Sponsor: Actelion
- |||||||||| Opsumit (macitentan) / Nippon Shinyaku, J&J
New P3 trial: Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument (clinicaltrials.gov) - Apr 25, 2013
P3, N=275, Recruiting, Sponsor: Actelion
- emiplacel (PLX-PAD) - Pluristem, Charite / University of Medicine Berlin
Enrollment open, PK/PD data: Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Apr 21, 2013
P1, N=9, Recruiting, Sponsor: United Therapeutics
Initiation date: May 2006 --> Oct 2006 Not yet recruiting --> Recruiting
- | Tracleer (bosentan) / J&J, Roche
Enrollment change: BOSAPAH: Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension (clinicaltrials.gov) - Apr 9, 2013
P2/3, N=43, Completed, Sponsor: University of Cincinnati
Not yet recruiting --> Recruiting N=60 --> 43
- Clinical: Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography (clinicaltrials.gov) - Apr 9, 2013
P=N/A, N=55, Recruiting, Sponsor: Medical University of Graz
- || Tracleer (bosentan) / J&J, Roche
Trial completion: BOSAPAH: Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension (clinicaltrials.gov) - Apr 9, 2013
P2/3, N=43, Completed, Sponsor: University of Cincinnati
N=60 --> 43 Active, not recruiting --> Completed
- Enrollment closed: Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography (clinicaltrials.gov) - Apr 8, 2013
P=N/A, N=25, Active, not recruiting, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- treprostinil / Generic mfg.
Enrollment closed: A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension (clinicaltrials.gov) - Apr 8, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: United Therapeutics
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Tracleer (bosentan) / J&J, Roche
Trial completion: FUTURE 2: Bosentan in Children With Pulmonary Arterial Hypertension Extension Study (clinicaltrials.gov) - Apr 7, 2013
P3, N=33, Completed, Sponsor: Actelion
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: Sommeil_HTAP: Screening for Sleep Hypoxemia in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 26, 2013
P=N/A, N=50, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed N=150 --> 50
- Trial completion: Sommeil_HTAP: Screening for Sleep Hypoxemia in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 26, 2013
P=N/A, N=50, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=150 --> 50 Recruiting --> Completed
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial termination: Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Mar 24, 2013
P2, N=23, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Terminated; Study was terminated due to serious adverse event (SAE)
- | epoprostenol intravenous / Generic mfg.
Enrollment closed: Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 13, 2013
P3, N=41, Active, not recruiting, Sponsor: Actelion
Recruiting --> Terminated; Study was terminated due to serious adverse event (SAE) Enrolling by invitation --> Active, not recruiting
- || epoprostenol intravenous / Generic mfg.
Trial completion: EPITOME-2: Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 13, 2013
P3, N=42, Completed, Sponsor: Actelion
Enrolling by invitation --> Active, not recruiting Recruiting --> Completed
- |||||||||| ambrisentan / Generic mfg.
New P3 trial: Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Mar 7, 2013
P3, N=120, Recruiting, Sponsor: GlaxoSmithKline
- Enrollment change, Gene therapy: PHACeT: Pulmonary Hypertension: Assessment of Cell Therapy (clinicaltrials.gov) - Mar 6, 2013
P1, N=7, Completed, Sponsor: Northern Therapeutics
Recruiting --> Completed N=18 --> 7
- Trial completion, Gene therapy: PHACeT: Pulmonary Hypertension: Assessment of Cell Therapy (clinicaltrials.gov) - Mar 6, 2013
P1, N=7, Completed, Sponsor: Northern Therapeutics
N=18 --> 7 Recruiting --> Completed
- ||| Tyvaso (treprostinil) / United Therapeutics Corp
Real-world evidence, Real-world: Tyvaso Dosing and Titration Evaluation: TyTRATE Registry (clinicaltrials.gov) - Feb 24, 2013
P=N/A, N=100, Recruiting, Sponsor: United Therapeutics
- emiplacel (PLX-PAD) - Pluristem, Charite / University of Medicine Berlin
New P1 trial, PK/PD data: Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Feb 19, 2013
P1, N=9, Recruiting, Sponsor: United Therapeutics
- Enrollment open, Heterogeneity, Compliance: Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging (clinicaltrials.gov) - Feb 18, 2013
P=N/A, N=15, Recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Qutenza (capsaicin) / Grunenthal, LTS Lohmann Therapy Systems
Trial completion: Qutenza (clinicaltrials.gov) - Feb 18, 2013
P2, N=11, Completed, Sponsor: Imperial College London
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial initiation date, Monotherapy: FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Feb 11, 2013
P3, N=349, Completed, Sponsor: United Therapeutics
Recruiting --> Completed Initiation date: May 2006 --> Oct 2006
- Enrollment closed: Oral Iron Supplementation in Pulmonary Hypertension (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=25, Active, not recruiting, Sponsor: The Cleveland Clinic
Initiation date: May 2006 --> Oct 2006 Recruiting --> Active, not recruiting
- ||||||| Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial completion, Monotherapy: FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Feb 11, 2013
P3, N=349, Completed, Sponsor: United Therapeutics
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp, Tyvaso (treprostinil) / United Therapeutics Corp
Enrollment closed: Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® (clinicaltrials.gov) - Feb 4, 2013
P2, N=30, Active, not recruiting, Sponsor: United Therapeutics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- simvastatin / Generic mfg.
Enrollment change: A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jan 30, 2013
P2, N=64, Terminated, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting N=92 --> 64
- Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial withdrawal, Combination therapy, Monotherapy: FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jan 28, 2013
P3, N=0, Withdrawn, Sponsor: United Therapeutics
N=92 --> 64 Terminated --> Withdrawn
- spironolactone / Generic mfg.
Trial withdrawal: Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure (clinicaltrials.gov) - Jan 24, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Colorado, Denver
Terminated --> Withdrawn Terminated --> Withdrawn
- Enrollment closed, MRI: Cardiac Magnetic Resonance Imaging and Pulmonary Perfusion (clinicaltrials.gov) - Jan 21, 2013
P=N/A, N=30, Active, not recruiting, Sponsor: University Hospital, Toulouse
Terminated --> Withdrawn Recruiting --> Active, not recruiting
- Trial completion: Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide (clinicaltrials.gov) - Jan 13, 2013
P2, N=10, Completed, Sponsor: Geno LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| ambrisentan / Generic mfg.
Trial completion: A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) (clinicaltrials.gov) - Jan 13, 2013
P3, N=383, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ranolazine ER / Generic mfg.
New P1 trial: A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 27, 2012
P1, N=16, Recruiting, Sponsor: University of Chicago
- carvedilol / Generic mfg.
Enrollment open: PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol) (clinicaltrials.gov) - Dec 19, 2012
P=N/A, N=68, Recruiting, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial completion: FREEDOM-C2: Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 6, 2012
P3, N=310, Completed, Sponsor: United Therapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- sodium nitrite inhalation (AIR001) / Savara
New P2 trial: Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05 (clinicaltrials.gov) - Nov 8, 2012
P2, N=17, Terminated, Sponsor: Aires Pharmaceuticals, Inc.
- sodium nitrite inhalation (AIR001) / Savara
New P2 trial: A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Nov 8, 2012
P2, N=29, Terminated, Sponsor: Aires Pharmaceuticals, Inc.
- | sodium nitrite inhalation (AIR001) / Savara
Trial completion, Combination therapy: Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects (clinicaltrials.gov) - Nov 7, 2012
P1, N=42, Completed, Sponsor: Aires Pharmaceuticals, Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- carvedilol / Generic mfg.
New P1/2 trial: Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children (clinicaltrials.gov) - Nov 5, 2012
P1/2, N=10, Recruiting, Sponsor: The Hospital for Sick Children
- ||| sildenafil / Generic mfg., tadalafil / Generic mfg.
Trial completion: Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR) (clinicaltrials.gov) - Nov 1, 2012
P=N/A, N=100, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed Active, not recruiting --> Completed
- treprostinil / Generic mfg., epoprostenol intravenous / Generic mfg.
Trial termination: Rapid Switch From Flolan to Remodulin in the Outpatient Clinic (clinicaltrials.gov) - Oct 29, 2012
P4, N=7, Terminated, Sponsor: United Therapeutics
Active, not recruiting --> Completed Recruiting --> Terminated; Due to availability of eligible subjects at center and enrollment competition with other studies.
- | Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment change: PATENT PLUS: Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters. (clinicaltrials.gov) - Oct 16, 2012
P2, N=18, Completed, Sponsor: Bayer
Recruiting --> Terminated; Due to availability of eligible subjects at center and enrollment competition with other studies. N=36 --> 18
- anastrozole / Generic mfg.
Enrollment open: Anastrozole in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Oct 15, 2012
P2, N=18, Recruiting, Sponsor: University of Pennsylvania
N=36 --> 18 Not yet recruiting --> Recruiting
- sildenafil / Generic mfg.
Trial completion: RESPONS PAH: Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Oct 2, 2012
P=N/A, N=22, Completed, Sponsor: Laval University
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial initiation date: PROWESS 15 Ext: Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 26, 2012
P3, N=49, Completed, Sponsor: Actelion
Recruiting --> Completed Initiation date: Jun 2008 --> Sep 2008
- | sorafenib / Generic mfg.
Trial completion: Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Sep 20, 2012
P1, N=12, Completed, Sponsor: University of Chicago
Initiation date: Jun 2008 --> Sep 2008 Active, not recruiting --> Completed
- | Trial termination: Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Aug 19, 2012
P2, N=162, Terminated, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Tracleer (bosentan) / J&J, Roche
Enrollment change, Combination therapy: Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH) (clinicaltrials.gov) - Aug 19, 2012
P4, N=40, Terminated, Sponsor: Hannover Medical School
Active, not recruiting --> Terminated N=72 --> 40